Human innate immune cell crosstalk induces melanoma cell senescence

Oncoimmunology. 2020 Aug 30;9(1):1808424. doi: 10.1080/2162402X.2020.1808424.

Abstract

Mononuclear phagocytes and NK cells constitute the first line of innate immune defense. How these cells interact and join forces against cancer is incompletely understood. Here, we observed an early accumulation of slan+ (6-sulfo LacNAc) non-classical monocytes (slanMo) in stage I melanoma, which was followed by an increase in NK cell numbers in stage III. Accordingly, culture supernatants of slanMo induced migration of primary human NK cells in vitro via the chemotactic cytokine IL-8 (CXCL8), suggesting a role for slanMo in NK cell recruitment into cancer tissues. High levels of TNF-α and IFN-γ were produced in co-cultures of TLR-ligand stimulated slanMo and NK cells, whereas much lower levels were contained in cultures of slanMo and NK cells alone. Moreover, TNF-α and IFN-γ concentrations in slanMo/NK cell co-cultures exceeded those in CD14+ monocyte/NK cell and slanMo/T cell co-cultures. Importantly, TNF-α and IFN-γ that was produced in TLR-ligand stimulated slanMo/NK cell co-cultures induced senescence in different melanoma cell lines, as indicated by reduced melanoma cell proliferation, increased senescence-associated β-galactosidase expression, p21 upregulation, and induction of a senescence-associated secretory phenotype (SASP). Taken together, we identified a role for slanMo and NK cells in a collaborative innate immune defense against melanoma by generating a tumor senescence-inducing microenvironment. We conclude that enhancing the synergistic innate immune crosstalk of slanMo and NK cells could improve current immunotherapeutic approaches in melanoma.

Keywords: NK cell; cytokines; melanoma; senescence; slanMo.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Cellular Senescence
  • Humans
  • Immunity, Innate
  • Killer Cells, Natural*
  • Melanoma*
  • Monocytes
  • Tumor Microenvironment

Grants and funding

Funded by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) – Project number 259332240 / RTG2099 (to F. Funck, K. Schäkel and A. Cerwenka), GRK 2099/2_AOBJ 654560 (to A. Cerwenka), SFB-TRR 156 Project B10 (to A. Cerwenka) and Project C02 (to K. Schäkel), the state of Baden-Württemberg foundation special program “Angioformatics single cell platform” (to A. Cerwenka), and SCHA 1693/1-1 (to K. Schäkel).